In this video, Arun Sanyal, MD, talks about how to make progress in the treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. He recently spoke about this topic at the 21st Annual Harvard Nutrition and Obesity Symposium on NAFLD.
Additional Resources:
Arun Sanyal, MD, is a professor of medicine at Virginia Commonwealth University in Richmond, Virginia.
TRANSCRIPT:
Hello, my name is Arun Sanyal, and I'm a professor of medicine at Virginia Commonwealth University.
The principal take-home point is that the anchor of the disease, the root cause, is a metabolic overload of the liver, which produces cell stress injury, leading to cell death, triggering inflammation.
Ongoing metabolic stress and ongoing cell death causes the inflammation to become chronic, which then triggers in turn a fiber generic response, leading to progressive fibrosis and remodeling of the liver towards cirrhosis.
So, if we are going to make progress in the treatment of NASH, we have to treat the root cause. Even in the future as we think about combination therapeutics, the anchor therapy has to be a metabolically targeted therapy.
Thank you everyone for listening to me today. I hope you enjoyed my presentation.
